MoonLake Skipped A $50 Million Loan Tranche, Leaving Its Next Borrowing Up To Lenders

The biotech's cash fell to $498.5 million as an undrawn $50.0 million tranche folded into a lender-approval tranche now up to $250.0 million.

Share
MoonLake Skipped A $50 Million Loan Tranche, Leaving Its Next Borrowing Up To Lenders

MoonLake Immunotherapeutics, a clinical-stage biotech developing treatments for inflammatory skin and joint diseases, never drew a $50.0 million loan tranche it had qualified for, its 10-Q filed Wednesday shows. The undrawn commitment now sits inside a sixth tranche that Hercules Capital and the other lenders can approve or refuse at their discretion.

A tranche earned, then left on the table

MoonLake hit the Tranche 4 milestone on June 21, 2026, when it announced 52-week results from its two Phase 3 trials in hidradenitis suppurativa, a painful chronic skin disease. It did not borrow during the availability window. After the window closed in the third quarter, the $50.0 million commitment was added to Tranche 6, which now runs up to $250.0 million, up from up to $200.0 million.

The prior quarter's 10-Q had said a fourth tranche was available until August 20, 2026. Borrowing it would have meant paying 8.45% interest plus an end-of-term charge of up to 6.95%. The company leaned on equity instead: a June offering at $20.00 a share and at-the-market sales at a weighted average of $18.52 a share. The shares closed at $11.70 on Tuesday.

Tranche 5, worth up to $100.0 million, is tied to FDA approval of the drug application. The company's earnings release says up to $400 million in non-dilutive funds remain available through the Hercules facility.

Cash down to $498.5 million

Cash, equivalents and short-term marketable debt securities fell to $498.5 million at September 30 from $537.0 million at June 30. Net cash used in operations was $185.2 million for the first nine months, against $137.2 million a year earlier. The company still says that cash lasts to mid-2028.

Accrued expenses jumped to $43.6 million from $27.1 million at June 30. A $17.0 million license-fee accrual to Merck's affiliate for FDA acceptance of the application drove much of it, and up to €299.6 million in further milestones could be payable. Purchase commitments to contract manufacturers and research organizations stood at $152.1 million, with $112.3 million due within a year.

The FDA clock

MoonLake submitted its Biologics License Application for sonelokimab, its sole drug candidate, on September 30. Management expects to hear within about 60 days whether the FDA accepts it, which the company expects by the end of November 2026. A decision on Priority Review is expected by mid-December 2026, and a U.S. launch is expected in the second half of 2027, if approved.

The FDA's acceptance decision, expected by the end of November, is the next test of the Hercules facility's larger tranches.

Sources

More on MoonLake Immunotherapeutics

All MoonLake Immunotherapeutics (MLTX) coverage →